EMD-52963

Single-particle
2.64 Å
EMD-52963
3D View Gallery
Deposition: 26/02/2025
Map released: 03/09/2025
Last modified: 22/10/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-52963
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 9q9l summary report (pdf.gz) Map and 9q9l FULL report (pdf.gz)
EMICSS annotations (xml)

HSV-1 prefusion glycoprotein B

EMD-52963

Single-particle
2.64 Å
EMD-52963
3D View Gallery
Deposition: 26/02/2025
Map released: 03/09/2025
Last modified: 22/10/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Human alphaherpesvirus 1 strain 17
Sample: Human alphaherpesvirus 1 Glycoprotein B
Fitted models: 9q9l

Deposition Authors: Vollmer B , Mulvaney T , Ebel H , Nentwig J , Gruenewald K
A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2.
Vollmer B , Ebel H , Rees R, Nentwig J , Mulvaney T , Schunemann J, Krull J, Topf M , Gorlich D, Grunewald K
(2025) Nature , 646 , 433 - 441
PUBMED: 40903574
DOI: doi:10.1038/s41586-025-09438-5
ISSN: 1476-4687
ASTM: NATUAS